Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A placebo-controlled, crossover trial of granisetron in SRI-induced sexualdysfunction
Autore:
Nelson, EB; Shah, VN; Welge, JA; Keck, PE;
Indirizzi:
Univ Cincinnati, Coll Med, Biol Psychiat Program, Dept Psychiat, Cincinnati, OH 45267 USA Univ Cincinnati Cincinnati OH USA 45267 sychiat, Cincinnati, OH 45267 USA Univ Cincinnati, Med Ctr, Ctr Biostat Serv, Cincinnati, OH 45267 USA Univ Cincinnati Cincinnati OH USA 45267 at Serv, Cincinnati, OH 45267 USA
Titolo Testata:
JOURNAL OF CLINICAL PSYCHIATRY
fascicolo: 6, volume: 62, anno: 2001,
pagine: 469 - 473
SICI:
0160-6689(200106)62:6<469:APCTOG>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
SEROTONIN REUPTAKE INHIBITORS; INDUCED ANORGASMIA; FLUOXETINE; CYPROHEPTADINE; REVERSAL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Citazioni:
25
Recensione:
Indirizzi per estratti:
Indirizzo: Nelson, EB Univ Cincinnati, Coll Med, Biol Psychiat Program, Dept Psychiat, POB 670559,231 Albert Sabin Way, Cincinnati, OH 45267 USA Univ CincinnatiPOB 670559,231 Albert Sabin Way Cincinnati OH USA 45267
Citazione:
E.B. Nelson et al., "A placebo-controlled, crossover trial of granisetron in SRI-induced sexualdysfunction", J CLIN PSY, 62(6), 2001, pp. 469-473

Abstract

Background: Sexual side effects are commonly associated with serotonin reuptake inhibitor (SRI) therapy. The mechanism underlying SRI-induced sexual dysfunction has been hypothesized to be mediated by direct serotonergic effects.. Evidence from open-label reports suggests that cyproheptadine, nefazodone, mirtazapine, and mianserin, which block one or more serotonin receptors, may reverse sexual side effects. The current study was a prospective, randomized, crossover trial comparing granisetron, a scrotonin-3 antagonist, with placebo in outpatients who developed sexual dysfunction during SRI treatment. Method: Thirty-one outpatients who were currently experiencing sexual dysfunction associated with SRIs were randomly assigned to double-blind treatment with granisetron (1-1.5 mg) or placebo for use 1 to 2 hours prior to sexual activity. Patients rated sexual symptoms after each trial using the Sexual Side Effect Scale (SSES). After 4 trials of the medication, patients crossed over to the other treatment for 3 more trials. Results: Twenty patients received at least 1 dose of placebo and granisetron. Analysis by repeated-mensures analysis of variance showed no significant effects of granisetron relative to placebo. Significant improvement between baseline and treatment-phase SSES scores was observed for both granisetron (p =.0004) and placebo (p =.0081). The study medication was generally well tolerated. Conclusion: The results of this study do not support the efficacy of granisetron (1-2 mg) in the treatment of SRI-associated sexual side effects. A significant placebo response may be associated with the treatment of SRI-induced sexual dysfunction.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 03:17:47